Use of pegylated il-10 to treat cancer

Abstract

Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.

1 . A method of inhibiting or reducing growth of a tumor or cancer comprising contacting the tumor with an effective amount of a pegylated interleukin-10 (PEG-IL-10). 
   
   
       2 . The method of  claim 1 , wherein the PEG-IL-10 comprises a methoxy-PEG-aldehyde (PALD-PEG) linker. 
   
   
       3 . The method of  claim 1 , wherein the PEG-IL-10 inhibits growth of the tumor or cancer. 
   
   
       4 . The method of  claim 1 , wherein the PEG-IL-10 reduces the size of the tumor or cancer. 
   
   
       5 . The method of  claim 1 , wherein PEG-IL-10 increases infiltration of CD8+ T cells into the tumor when compared to non-pegylated IL-10. 
   
   
       6 . The method of  claim 1 , wherein PEG-IL-10 increases the expression of at least one inflammatory cytokine. 
   
   
       7 . The method of  claim 6 , wherein the inflammatory cytokine is selected from the group consisting of IFNγ, IL-4, IL-6, IL-10, and RANK-ligand (RANK-L). 
   
   
       8 . The method of  claim 1 , wherein the PEG-IL-10 is co-administered with at least one chemotherapeutic agent. 
   
   
       9 . The method of  claim 8 , wherein the chemotherapeutic agent is at least one of the chemotherapeutic agents of Table 16. 
   
   
       10 . The method of  claim 1 , wherein the tumor or cancer is selected from the group consisting of colon cancer, ovarian cancer, breast cancer, melanoma, lung cancer, glioblastoma, and leukemia. 
   
   
       11 . A method of treating a subject suffering from a cancer or tumor comprising administering to the subject an effective amount of PEG-IL-10. 
   
   
       12 . The method of  claim 11 , wherein the PEG-IL-10 comprises a methoxy-PEG-aldehyde (PALD-PEG) linker. 
   
   
       13 . The method of  claim 11 , wherein the PEG-IL-10 inhibits growth of the cancer or tumor. 
   
   
       14 . The method of  claim 11 , wherein the PEG-IL-10 reduces the size of the tumor or cancer. 
   
   
       15 . The method of  claim 11 , wherein PEG-IL-10 increases infiltration of CD8+ T cells into the tumor when compared to non-pegylated IL-10. 
   
   
       16 . The method of  claim 11 , wherein PEG-IL-10 increases the expression of at least one inflammatory cytokine. 
   
   
       17 . The method of  claim 16 , wherein the inflammatory cytokine is selected from the group consisting of IFNγ, IL-4, IL-6, IL-10, and RANK-L. 
   
   
       18 . The method of  claim 11 , wherein the PEG-IL-10 is co-administered with at least one chemotherapeutic agent. 
   
   
       19 . The method of  claim 18 , wherein the chemotherapeutic agent is at least one of the chemotherapeutic agents of Table 16. 
   
   
       20 . The method of  claim 11 , wherein PEG-IL-10 reduces metastasis of a cancer or tumor. 
   
   
       21 . The method of  claim 11 , wherein the tumor or cancer is selected from the group consisting of colon cancer, ovarian cancer, breast cancer, lung cancer, melanoma, glioblastoma, and leukemia. 
   
   
       22 . The method of  claim 11 , wherein the subject is human. 
   
   
       23 . The method of  claim 22 , wherein the PEG-IL-10 is human PEG-IL-10 (PEG-hIL-10).